Hospital
Jiangsu Cancer Hospital江苏省肿瘤医院
At a glance
Published values only, each read from the record this page is built on. The listings behind them are in the section below.
-
National key clinical specialties 2 at evidence level A or B
-
Published research 11 PubMed records we hold for this hospital (the newest twenty per hospital)
-
Registered studies 7 records we hold for this hospital, as registered
Rankings & accreditation
These listings are published by the bodies that run them, not by this site. Every line carries the year it was published and a link to its source; this is not a paid or promoted listing.
Fudan specialty reputation ranking
| Item | Rank / tier | Year | Caliber | Source |
|---|---|---|---|---|
| Medical Oncology 肿瘤学 | #9 | 2023 | Place in the specialty reputation ranking | https://www.fdygs.com/news2023-1.aspx |
National key clinical specialties
| Specialty | Evidence | Source |
|---|---|---|
| Medical Oncology 肿瘤科 | Level B | https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579 |
| Thoracic Surgery 胸外科 | Level B | https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579 |
Batch is not published by the source.
2 specialty rows, each carrying its own evidence level.
Each row carries its own evidence level and its own source. Level definitions are on the methodology page.
Values written in Chinese are quoted as published by the source.
Administrative grade
| Item | Rank / tier | Year | Caliber | Source |
|---|---|---|---|---|
| Grade as published Tier 3, class A 三级甲等 | Tier 3, class A | As of 2026-05-08 截至 2026-05-08 | An administrative designation, not a ranking; the date is the list's own publication date, not the year the grade was awarded | The source of this record, at the foot of this page |
Conditions treated here
Conditions this site files under the specialties above. It is a record of the listings, not a recommendation.
For international patients
A line appears here only where we hold a record for it. A line that is missing has not been verified - ask us and we will put the question to the hospital.
Hospital details
- Chinese name
- 江苏省肿瘤医院
- English name
- Jiangsu Cancer Hospital
- Grade
- Tier 3, class A 三级甲等
- Grade list as published
- As of 2026-05-08 截至 2026-05-08
Values written in Chinese are quoted as published by the source.
The grade list reference is the date or review batch the official list was published under; it is quoted in the source's language.
Also known as
- Jiangsu Institute of Cancer Research
- The Affiliated Cancer Hospital of Nanjing Medical University
Evidence for this condition
Selected using official public data sources
-
Colorectal cancer
Published research
- Association Between Health-Related Quality of Life In Patients with Colorectal Cancer and Their Informal Caregivers. Advances in therapy, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #9 in the Fudan list.
-
Breast cancer
Published research
- Raman spectral unmixing of breast cancer tissues via continuous wavelet transform and TransUnet. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2026
- LC-MS/MS-based clinical value exploration of the methionine cycle in luminal breast cancer. Oncology letters, 2026
2 more published studies
PubMed indexes 4 papers on this condition that name this hospital.
Also ranked: Medical Oncology #9 in the Fudan list.
-
Lung cancer
National key clinical specialty
- Thoracic Surgery (level B) https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579
Published research
- APG-1252 enhances the anticancer role of paclitaxel in non-small-cell lung cancer cells by suppressing the extracellular regulated protein kinases/myeloid cell leukemia 1 pathway. Anti-cancer drugs, 2026
- Histone H3K18 Lactylation Drives Immunosuppression by Upregulating CD38 in Myeloid-Derived Suppressor Cells in Lung Cancer. Cancer immunology research, 2026
1 more published study
PubMed indexes 3 papers on this condition that name this hospital.
Also ranked: Medical Oncology #9 in the Fudan list.
-
Cervical cancer
Published research
- RSRC1 is a candidate progression-associated biomarker in cervical cancer linked to p53/CDK2-associated cell-cycle signaling. European journal of pharmacology, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #9 in the Fudan list.
-
Stomach cancer
Published research
- Laminin γ2-ITGβ1-PD-L1 axis mediates gastric cancer cell heterogeneity in response to GCMSCs via FAK/YAP pathway. Cellular signalling, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #9 in the Fudan list.
-
Esophageal cancer
National key clinical specialty
- Thoracic Surgery (level B) https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579
Published research
- Protocol for a cohort study: evaluating the effect of neoadjuvant immunochemotherapy on intraoperative remifentanil consumption during IoC2-guided anesthesia in elderly patients with esophageal cancer. Annals of medicine, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #9 in the Fudan list.
-
Pancreatic cancer
Fudan specialty reputation ranking 2023
- Medical Oncology #9 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579
-
Bone and soft tissue sarcoma
Fudan specialty reputation ranking 2023
- Medical Oncology #9 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579
Other hospitals in Nanjing
Source & evidence
- Source URL
- https://www.fdygs.com/news2023-1.aspx
- Source scheme
- https
- Source type
- Third-party compilation
- Evidence level
- B - hospital self-statement or authoritative media
- Retrieved on
- 2026-09-24